Life Scientist > Biotechnology

Trial demonstrates long life tissue heart valves

05 December, 2011 by Dylan Bushell-Embling

Tissue treated with Allied Healthcare Group's ADAPT tissue engineering technology showed significantly reduced calcification in preclinical trials.


Patrys raises $3.4m to fund product trials

05 December, 2011 by Dylan Bushell-Embling

Cancer treatment development company Patrys (ASX:PAB) has raised $3.4m in an oversubscribed placement to fund clinical trials for its antibody-based products.


News in movers and shakers

05 December, 2011 by Dylan Bushell-Embling

CBio appoints new chairman, interim MD; AusBiotech CEO joins Research Australia board; Timothy Waugh named Hatchtech CEO.


Manufacturing taskforce an opportunity for life science sector

01 December, 2011 by Tim Dean

AusBiotech will be lobbying for a greater emphasis on biopharma and medical devices on the newly established Prime Minister's Taskforce on Manufacturing.


Victorian Government establishes Biotechnology Advisory Council

01 December, 2011 by Tim Dean

Biotechnology Advisory Council will advise the government on current and emerging opportunities and threats to the biotechnology sector and aid in implementation of policy.


AstraZeneca invests in Victoria's NeuProtect

01 December, 2011 by Dylan Bushell-Embling

Victorian biopharma NeuProtect has added AstraZeneca's venture capital subsidiary, MedImmune Ventures, as a new investor.


AusBiotech CEO appointed to Research Australia Board

01 December, 2011 by AusBiotech

AusBiotech CEO, Dr Anna Lavelle, has been appointed to the Board of Research Australia, effective from the annual general meeting held recently.


Immuron signs distribution deal worth up to $113 million

29 November, 2011 by Dylan Bushell-Embling

Immuron (ASX:IMC) has secured a multi-market distribution deal worth up to C$115.5 million ($112.7m) for its debut OTC antibody product, Travelan.


Clinical trials data sought for first-of-kind study

29 November, 2011 by AusBiotech

The Federal Government is conducting a first-of-its-kind study to gauge the level of privately funded clinical research activity in Australia.


iSonea ramps up product efforts

29 November, 2011 by Dylan Bushell-Embling

Acoustic respiratory monitoring company iSonea (ASX:ISN) will use funds from a $4.3 million capital raising to expedite the search for a distribution partner.


Stem cells undergo evolution in the lab

28 November, 2011 by Tim Dean

A new study has found cultured human embryonic stem cells undergo selection for greater self-renewal, which has implications on stem cell therapies.


Organovo wins innovation award for 3D bioprinter

28 November, 2011 by Dylan Bushell-Embling

Start-up Organovo and partner Inventech have won this year's AusIndustry-sponsored Engineering Innovation Award for their 3D bioprinter product.


Feature: Beyond the hype of algal biofuels

25 November, 2011 by Fiona Wylie

Algal biofuels have been much hyped, but the reality is getting closer every day. Chemical engineer and algal biofuels researcher David Lewis brings algae down to earth.


Government supports gene patent reform

24 November, 2011 by Tim Dean

The Labor Government has responded to three key reports on Australia's patent system, endorsing many reforms affecting biotechnology and gene patents.


Inquiry on medical devices delivers report

24 November, 2011 by AusBiotech

The Senate Standing Committees on Community Affairs has completed its Inquiry into 'The Regulatory Standards for the Approval of Medical Devices' and tabled its report in the Senate on Tuesday night.


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd